R-verapamil (CS 02)
/ ALK-Abello
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 07, 2021
Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models.
(PubMed, PLoS One)
- "Hence, R-verapamil may be an optimal DM treatment as it is safe, improves glycemic control, and preserves β-cell function both as monotherapy and in combination with metformin or acarbose. R-Verapamil has potential for delaying or arresting DM progression and improving patients' quality of life."
Journal • Preclinical • Cardiovascular • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • IL6 • SSTR • SSTR2
June 09, 2020
CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)
(clinicaltrials.gov)
- P2; N=201; Completed; Sponsor: Center Laboratories, Inc.; Recruiting ➔ Completed; Trial completion date: Mar 2021 ➔ Apr 2020; Trial primary completion date: Oct 2020 ➔ Apr 2020
Clinical • Combination therapy • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 2
Of
2
Go to page
1